Bottom Line: S&N manages to stay healthy
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.SCEPTICS looking for signs of margin pressure at Smith & Nephew in the price-conscious healthcare environment have been disappointed yet again by the group's half-year figures.
Operating margins increased from 16.5 to 17.1 per cent. Pricing pressure applies to less than 20 per cent of S&N's sales and cost-cutting not only offset the impact of this but enhanced the effect of price increases roughly in line with inflation elsewhere.
Excluding the eye-boggling pounds 148m exceptional loss on the sale of Ioptex, its ill-fated intraocular lens business in the US, pre-tax profits rose by 12 per cent to pounds 82.2m or by an underlying 8 per cent after adjusting for a reclassification of convertible preference share dividends.
The dividend is up by 7 per cent, in line with the growth in underlying earnings.
Sales growth in S&N's higher- margin products in wound management, casting and support, and trauma and arthroscopy is bowling along at over 10 per cent. Growth in orthopaedic implants, where buyers are more able to defer purchases, slowed to 8 per cent, depressed by poor conditions in Spain and France. Commodity products like surgical gloves are in retreat but consumer healthcare grew 10 per cent, helped by the relaunch of the Simple toiletries brand.
Strong cash generation has reduced gearing to 4 per cent and leaves the company able to contemplate a variety of horizontal acquisitions. Margins may not have much further to rise, so earnings are likely to follow underlying sales growth of 7 per cent. At this stage of the cycle a p/e of 14.5, assuming pre-tax profits of pounds 180m and a yield of 4.2 per cent at 154.5p, looks fair value but no more than that.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments